Researchers have announced the development of a pioneering blood test for the diagnosis of Myalgic Encephalomyelitis (ME), also known as Chronic Fatigue Syndrome. ME, a complex and often misunderstood illness, has long plagued patients with undiagnosed suffering, with severe cases leading to devastating outcomes. The NHS is currently reviewing ME following the tragic death of Maeve Boothby O’Neill, a 27-year-old who passed away under distressing circumstances.
The new DNA blood test, created by a team including lead researcher Prof Dmitry Pshezhetskiy from the University of East Anglia (UEA), aims to accurately identify individuals with ME. This breakthrough technology could potentially revolutionize the diagnosis of Long Covid as well. Prof Pshezhetskiy emphasized the significance of this advancement, highlighting the challenges faced by ME patients who often endure misdiagnoses and lack of proper medical attention.
ME is characterized by symptoms such as post-exertional malaise, pain, cognitive impairment, and severe fatigue, with its causes remaining unknown and no definitive diagnostic tools available until now. The research team, in collaboration with experts from Oxford Biodynamics (OBD), utilized innovative EpiSwitch technology to analyze DNA folding patterns in ME patients, identifying a distinct pattern unique to individuals with the condition.
Published in the Journal of Translational Medicine, the study revealed that the blood test displays a high sensitivity of 92% and specificity of 98%, potentially offering a reliable diagnostic tool for ME if approved by UK regulators. Prof Pshezhetskiy emphasized the test’s role in understanding the biological mechanisms of ME, paving the way for improved treatments and management strategies.
Furthermore, OBD’s chief scientific officer, Alexandre Akoulitchev, emphasized the importance of using epigenetic markers in the test, underscoring the dynamic nature of these markers compared to fixed genetic codes. This approach significantly contributes to the test’s accuracy in diagnosing ME, addressing a crucial need for efficient diagnostics in complex illnesses.
Experts have noted that individuals of white ethnicity and middle-aged women are at a higher risk of developing ME, with prevalence rates skewed towards women. The tragic case of Maeve Boothby O’Neill’s death has prompted a call for urgent action in improving care and research funding for ME, as highlighted in the groundbreaking “prevention of future deaths report” issued last year.
While the new blood test shows promising results, experts caution that further validation and larger studies are necessary to confirm its efficacy across different stages of ME and rule out false positives. Dr. Charles Shepherd from The ME Association stressed the importance of ensuring the test’s sensitivity and specificity in diagnosing ME accurately, urging continued research to validate these findings.
Retired consultant physician Dr. Alastair Miller expressed optimism but raised concerns regarding the study’s control group, urging comprehensive testing across various chronic conditions to avoid inflated expectations. Despite the remarkable accuracy reported, thorough validation and scrutiny are essential to ensure the test’s reliability and applicability in clinical settings.